Harmony Biosciences (HRMY) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Schrodinger (SDGR) over the past year, gaining 45.4% versus a gain of 35.4%. Over five years, HRMY leads with a -0.2% price change compared with -50.7% for SDGR. Harmony Biosciences is the larger company by market cap ($2.29 billion vs $2.04 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | SDGR |
|---|---|---|
| Share price | $39.34 | $27.29 |
| Market cap | $2.29B | $2.04B |
| 1-day change | -0.05% | -5.57% |
| YTD return | +5.13% | +52.63% |
| 1-year return | +45.43% | +35.37% |
| 5-year return | -0.15% | -50.70% |
| P/E ratio (TTM) | 12.69 | — |
| Forward P/E | 5.62 | — |
| EPS (TTM) | $3.10 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.49 | $33.78 |
| 52-week low | $25.52 | $10.95 |
| Distance from 52-week high | -9.54% | -19.21% |
| Analyst consensus | buy | none |
| Avg. price target upside | +21.10% | -21.47% |
| Average volume | 893.96K | 1.69M |
| Shares outstanding | 58.24M | 65.64M |
| Employees | 293 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed SDGR by 10.1 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
HRMY vs SDGR FAQ
Which is bigger, Harmony Biosciences or Schrodinger?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.29B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, HRMY or SDGR?
HRMY returned +45.43% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.